⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 15, 2025Open Access

Supplementary Figure S1 from Clinical Evaluation of M1-c6v1 Oncolytic Virus Combined with Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma

Chan Xie Xingrong Zheng Songmin He Wenxiong Xu Wenbo Zhu Guangmei Yan Liang Peng

View Full Paper

Ask AI

Bookmark

Share

Key Points

AFP levels correlated with treatment efficacy in subjects, implying a potential biomarker for assessing the response.
Seven efficacy-evaluable subjects showed varying AFP levels linked closely to outcomes, indicating individual response variability.
This observational analysis investigates treatment impacts on AFP levels in advanced hepatocellular carcinoma patients.
These findings highlight the need for further research to validate AFP as a reliable therapeutic indicator.

Implication

Analysis shows AFP levels correlate with treatment efficacy in patients with hepatocellular carcinoma, suggesting therapeutic insights.

Abstract

Supplementary Figure 1. The AFP levels of 7 efficacy-evaluable subjects and their correlation with treatment efficacy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Xie et al. (2025) studied this question.

synapsesocial.com/papers/68f199c5de32064e504dce0b https://doi.org/10.1158/1078-0432.30363217

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S2 from Clinical Evaluation of M1-c6v1 Oncolytic Virus Combined with Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma2025
2Supplementary Figure S5 from Clinical Evaluation of M1-c6v1 Oncolytic Virus Combined with Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma2025
3Supplementary Figure S4 from Clinical Evaluation of M1-c6v1 Oncolytic Virus Combined with Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma2025
4Data from Clinical Evaluation of M1-c6v1 Oncolytic Virus Combined with Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma2025
5Clinical Evaluation of M1-c6v1 Oncolytic Virus Combined with Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma.2025 · 12 citations

More related papers

Supplementary Figure 1 from Efficacy and safety of stereotactic body radiotherapy combined with Camrelizumab and Apatinib in hepatocellular carcinoma patients with portal vein tumor thrombus2024
Efficacy of targeted hepatocellular carcinoma therapy using modified response evaluation criteria in solid tumors and alpha-fetoprotein: A single center retrospective exploratory study2026
Supplementary Figure S8 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer2024